yawrp

You might enjoy this piece, covers a few of the tradeoffs you mention https://hex.tech/blog/a-pragmatic-approach-to-live-collabora...

Interesting piece from last week comparing OT, CRDT, and Figma's hybrid approach (good explainers of each too): https://hex.tech/blog/a-pragmatic-approach-to-live-collabora...

For one, there are more candidates than capacity to run clinical trials. Costs & timelines for those have been going up over time. Lots of high-potential compounds just sitting on the shelf.